Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

Source: OncLive, August 2020

Spartalizumab in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet the primary end point of investigator-assessed progression-free survival (PFS) in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma, according to an update on the phase 3 COMBI-i trial (NCT02967692).1

“While the COMBI-i trial did not reach its primary end point, the study’s findings give us valuable insights into the role the investigational immunotherapy spartalizumab may play in future cancer therapy combinations and underscore the previously established importance of [dabrafenib plus trametinib] for these patients,” John Tsai, MD, head of Global Drug Development and chief medical officer at Novartis, stated in a press release.

The pharmaceutical company will continue to examine the data from the trial, along with the study investigators, and the results will be submitted for presentation at an upcoming medical meeting.

READ THE ORIGINAL FULL ARTICLE